An easy-to-use antimicrobial hydrogel effectively kills bacteria, fungi, and influenza virus
Various drug resistant pathogens such as bacteria, fungi and viruses enter a host through different routes, which can lead to health-related problems and even fatalities. Propagation of these infectious microbes majorly occurs through the mucosal openings or upon topical contact. To curb their transmission or to cure infections associated with these pathogens, herein we describe the development of an antimicrobial hydrogel, based on a water soluble quaternary lipophilic polyethyleneimine derivative (QPEINH-C6). The cationic polymer QPEINH-C6 exhibited antibacterial activity against drug-resistant Gram-positive bacteria (MI...
Source: Current Awareness Service for Health (CASH) - April 21, 2022 Category: Consumer Health News Source Type: news

Diflucan (fluconazole)
Title: Diflucan (fluconazole)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 12/6/2021 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - December 6, 2021 Category: Drugs & Pharmacology Source Type: news

Janssen Showcases Commitment to Advancing Scientific Innovation in Pulmonary Arterial Hypertension (PAH) at CHEST 2021 Annual Meeting
TITUSVILLE, N.J. – October 14, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today 11* abstracts highlighting data from its pulmonary hypertension (PH) portfolio will be presented at CHEST 2021, the annual meeting of the American College of Chest Physicians, held virtually October 17-20.Data presentations from eight abstracts will provide additional evidence supporting the role of objective multiparameter risk assessment approaches in helping to optimize treatment and care for pulmonary arterial hypertension (PAH), as well as the impact of earlier and comprehensive therapy with UPTRAVI...
Source: Johnson and Johnson - October 14, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

The Most Important Thing Rich Countries Can Do to Help India Fight COVID-19
The Biden Administration is debating whether COVID-19 vaccine patents should be temporarily waived, given the devastating humanitarian crisis unfolding in India from the virus. There are two key factors that should drive the Biden team to agree to do so: first, there is strong precedent on waiving patents in the context of public health emergencies; second, the real-world effectiveness of most COVID-19 vaccines against symptomatic disease and transmission can temper the disaster. The Biden Administration will be making its decision on lifting some patent restrictions as early as May 5. India faces a catastrophe, with ove...
Source: TIME: Health - May 5, 2021 Category: Consumer Health News Authors: Dr. Monica Gandhi Tags: Uncategorized COVID-19 India Source Type: news

ANI Pharmaceuticals Announces Acquisition of Fluconazole Tablets
BAUDETTE, Minn., July 6, 2020 -- (Healthcare Sales & Marketing Network) -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the acquisition of Fluconazole Tablets USP, 50mg, 100mg, 150mg, and 200mg from a private company for $3.0... Biopharmaceuticals, Acquisitions ANI Pharmaceuticals, Fluconazole, candidiasis, candida (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 6, 2020 Category: Pharmaceuticals Source Type: news

Musculoskeletal Malformations Up With Fluconazole in Pregnancy
THURSDAY, May 21, 2020 -- Use of oral fluconazole for treatment of vulvovaginal candidiasis in the first trimester of pregnancy is associated with musculoskeletal malformations, but not with oral clefts or conotruncal malformations, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 21, 2020 Category: Pharmaceuticals Source Type: news

() - new on RxList
Tolsura (itraconazole capsules) and Diflucan (fluconazole) are azole antifungals used to treat various types of infections. (Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 13, 2019 Category: Drugs & Pharmacology Source Type: news

Antifungal prophylaxis with posaconazole versus fluconazole in children with neutropenia following hematopoietic stem cell transplanation
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 25, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Posaconazole vs fluconazole eficacy and safety of antifungal prophylaxis on patients with allogenic stem cell transplantation. Experience of a mexican center
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 25, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Antifungal prophylaxis with fluconazole or fluconazole followed by posaconazole in high risk patients in allogeneic setting
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 25, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Fluconazole was equal to mold-active drugs in preventing early invasive fungal disease after allogeneic stem cell transplantation regardless of transplantation type
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 19, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Antifungal prophylaxis with nebulized liposomal amphotericin B and fluconazole is effective and safe in the early phase of allogenic hematopoietic stem cell transplantation
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 19, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Randomized Trial of Micafungin Versus Fluconazole in Prophylaxis Against Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 20, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

FDA Drug Safety Communication:Use of long-term, high-dose Diflucan (fluconazole) during pregnancy may be associated with birth defects in infants
[8-03-2011] The U.S. Food and Drug Administration (FDA) is informing the public that chronic, high doses (400-800 mg/day) of the antifungal drug Diflucan (fluconazole) may be associated with a rare and distinct set of birth defects in infants whose mothers were treated with the drug during the first trimester of pregnancy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 28, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Drug Safety Communication: FDA to review study examining use of oral fluconazole (Diflucan) in pregnancy
The U.S. Food and Drug Administration (FDA) is evaluating the results of a Danish study1 that concludes there is a possible increased risk of miscarriage with the use of oral fluconazole (Diflucan) for yeast infections. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 18, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news